Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine

Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing

(2015) Sofia R. Gameiro et al.   Oncotarget

A phase I study of cabozantinib (XL184) in patients with renal cell cancer

(2014) T. K. Choueiri et al.   ANNALS OF ONCOLOGY

Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET

(2014) Q. Xiang et al.   CLINICAL CANCER RESEARCH

IL-2: The First Effective Immunotherapy for Human Cancer

(2014) S. A. Rosenberg   JOURNAL OF IMMUNOLOGY

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine Improves Survival in a Spontaneous Prostate Cancer Model

(2013) A. Ardiani et al.   CLINICAL CANCER RESEARCH

Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer

(2013) David Viola et al.   Future Oncology

Cabozantinib in Progressive Medullary Thyroid Cancer

(2013) Rossella Elisei et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination Therapy with Local Radiofrequency Ablation and Systemic Vaccine Enhances Antitumor Immunity and Mediates Local and Distal Tumor Regression

(2013) Sofia R. Gameiro et al.   PLoS One

Defining the Molecular Signature of Chemotherapy-Mediated Lung Tumor Phenotype Modulation and Increased Susceptibility to T-Cell Killing

(2012) Sofia R. Gameiro et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

(2012) David C. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

IFN-  in the Treatment of Melanoma

(2012) A. A. Tarhini et al.   JOURNAL OF IMMUNOLOGY

Overcoming Resistance to Antiangiogenic Therapies

(2012) S. Tejpar et al.   ONCOLOGIST

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

(2012) Y. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Tipping Point for Combination Therapy: Cancer Vaccines With Radiation, Chemotherapy, or Targeted Small Molecule Inhibitors

(2012) James W. Hodge et al.   SEMINARS IN ONCOLOGY

Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors

(2012) Barbara Sennino et al.   Cancer Discovery

Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses

(2011) Sofia R. Gameiro et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer

(2011) W.-K. You et al.   CANCER RESEARCH

Hepatocyte growth factor-induced c-Src-phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway inhibits dendritic cell activation by blocking IκB kinase activity

(2011) Eshu Singhal et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy

(2011) Benedetto Farsaci et al.   INTERNATIONAL JOURNAL OF CANCER

Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer

(2011) Takayuki Kosaka et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

(2011) Razelle Kurzrock et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors

(2010) F. Shojaei et al.   CANCER RESEARCH

Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine

(2010) Benedetto Farsaci et al.   INTERNATIONAL JOURNAL OF CANCER

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hepatocyte Growth Factor Modulates Interleukin-6 Production in Bone Marrow Derived Macrophages: Implications for Inflammatory Mediated Diseases

(2010) Gina M. Coudriet et al.   PLoS One

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

(2009) Celestia S. Higano et al.   CANCER

Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations

(2009) Amanda L. Boehm et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Intraepithelial Effector (CD3+)/Regulatory (FoxP3+) T-Cell Ratio Predicts a Clinical Outcome of Human Colon Carcinoma

(2009) Frank A. Sinicrope et al.   GASTROENTEROLOGY